Skin cancer,
Immunotherapy,
Risk,
Patient,
SAN,
RP1,
University,
MD Anderson Cancer Center,
Society,
AACR,
Carcinoma,
CSCC,
SITC,
PD-L1,
Skin,
Pharmaceutical industry The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Key Points:
- The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
- In the evaluable patient population (n=23), 20 had cutaneous squamous cell carcinoma (CSCC) and three had merkel cell carcinoma.
- Of note, a patient treated with RP1 for CSCC also had a complete response of a new primary basal cell carcinoma which appeared post baseline.
- RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers.
The inducement awards consist of a non-qualified stock option to purchase 75,000 shares of the Company's common stock and restricted stock units representing 50,000 shares of the Company's common stock.
Key Points:
- The inducement awards consist of a non-qualified stock option to purchase 75,000 shares of the Company's common stock and restricted stock units representing 50,000 shares of the Company's common stock.
- The option has an exercise price of $7.73 per share, which is equal to the closing price of the Company's common stock on the date of grant.
- The inducement awards were granted under the Company's previously approved Employment Commencement Incentive Plan and were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4).
- While the inducement awards were granted outside of Replimune's 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under the plan.
Development,
Growth,
Skin cancer,
Immunotherapy,
Genentech,
Philip,
Patient,
Lung,
RP1,
Skin,
Cancer,
Melanoma,
Retirement,
Marketing,
BLA WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.
Key Points:
- Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024.
- Mr. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors.
- Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer.
- Prior to joining Replimune, Dr. Patel served as franchise head for lung, skin and rare cancers at Genentech.
WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held in San Diego, CA from April 5-10, 2024.
Key Points:
- WOBURN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held in San Diego, CA from April 5-10, 2024.
- Details of the presentations are as follows:
WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following three conferences:
Key Points:
- WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following three conferences:
Live webcasts of the Leerink and Barclays fireside chats will be available in the Investors section of Replimune’s website at www.replimune.com.
- A replay will be available for 30 days following the conference.
Retrieved on:
Thursday, February 8, 2024
Carcinoma,
Neoplasm,
Melanoma,
NMSC,
Merkel-cell carcinoma,
REPL,
Angiosarcoma,
SITC,
PFS,
Clinical trial,
Research,
RECIST,
Society,
Hercules,
Patient,
CSCC,
Type,
FDA,
Marketing,
Investment,
RP1,
Food,
MCC,
Immunotherapy,
Skin,
Nivolumab,
Uveal melanoma,
Annual general meeting,
BLA,
RP2,
Pharmaceutical industry WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
Key Points:
- WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
- We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024.
- Selling, general and administrative expenses included $4.5 million in stock-based compensation expenses for the third quarter ended December 31, 2023.
- Net Loss: Net loss was $51.1 million for the third quarter ended December 31, 2023, as compared to a net loss of $39.7 million for the third quarter ended December 31, 2022.
Retrieved on:
Tuesday, January 16, 2024
DISCO,
Stanford University,
Patient,
Sofinnova,
Therapy,
Research,
Colorectal cancer,
Umoja,
University,
Map,
COYA,
Pfizer,
Drug discovery,
EVP,
Roche,
Spacecraft,
SCLC,
ETH,
BMS,
Protein,
CDO,
Genome,
Bayer,
Doctor of Philosophy,
Proteomics,
Merck Group,
Carcinoma Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
Key Points:
- Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
- COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
- The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
- Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.
Retrieved on:
Tuesday, January 16, 2024
DISCO,
Stanford University,
Patient,
Sofinnova,
Therapy,
Research,
Colorectal cancer,
Umoja,
University,
Map,
COYA,
Pfizer,
Drug discovery,
EVP,
Roche,
Spacecraft,
SCLC,
ETH,
BMS,
Protein,
CDO,
Genome,
Bayer,
Doctor of Philosophy,
Proteomics,
Merck Group,
Carcinoma Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
Key Points:
- Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
- COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
- The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
- Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.
Retrieved on:
Thursday, December 28, 2023
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA.
Key Points:
- WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 11:15 AM PT at the Westin St. Francis Hotel in San Francisco, CA.
- A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com.
- A replay will be available for 30 days following the conference.
Retrieved on:
Tuesday, December 5, 2023
Chills,
CRS,
Melanoma,
RP1,
CRC,
Food,
Melanoma Research,
RECIST,
NMSC,
Transplant,
Diarrhea,
FDA,
Cytokine release syndrome,
Colorectal cancer,
SCCHN,
Type,
RP3,
CRR,
Fatigue,
Headache,
Nausea,
Itch,
Myocarditis,
Incidence,
Nivolumab,
Influenza-like illness,
Research,
Clinical trial,
Injection site reaction,
Myalgia,
CSCC,
Skin cancer,
HCC,
Weakness,
Society,
Head,
Appetite,
RP2,
Regeneron Pharmaceuticals,
Carcinoma,
Investment,
Webcast,
Patient,
Lipase,
Angiosarcoma,
MCC,
Vomiting,
Neck,
Uveal melanoma,
Rash,
BLA,
Pharmaceutical industry The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
Key Points:
- The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
- The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
- The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
- RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.
